The Lung Therapeutics Program (LTP) initiates by identifying individuals with known or suspected pulmonary conditions. For patients with suspected disease, bedside spirometry serves as the clinical cornerstone—providing objective evidence of pulmonary compromise to guide the development of a targeted treatment plan. For individuals with an established diagnosis, this testing is used to systematically monitor the efficacy of ongoing treatments. As the clinical gold standard, bedside spirometry is essential for both confirming the presence of lung disease and optimizing therapeutic outcomes.